About

Retro Biosciences focuses on extending healthy human lifespan by developing therapeutics that target the cellular mechanisms of aging. The company works on three main programs: cellular reprogramming, plasma-inspired therapeutics, and autophagy, each at different stages of development. By addressing the root causes of age-related diseases, Retro Biosciences aims to reduce healthcare costs associated with these conditions, which make up a significant portion of U.S. healthcare spending. The company utilizes advanced technologies like single-cell multi-omics and computational biology to support its research. With $180 million in funding, Retro Biosciences is positioned to advance its therapeutic candidates towards clinical applications, aiming to make significant contributions to age-related disease prevention.

Simplify's Take

What believers are saying

• Retro Biosciences' mission to extend healthy human lifespan by ten years offers a compelling and impactful vision for employees.
• The company's robust pipeline and advanced technologies like single-cell multi-omics and computational biology provide ample opportunities for innovation and career growth.
• Strong financial backing and high-profile investments, such as from Sam Altman, ensure long-term stability and resources for research and development.

What critics are saying

• The ambitious goal of extending human lifespan by ten years involves high scientific and regulatory uncertainties.
• Dependence on successful clinical trials and commercialization of therapeutic candidates poses significant risks.

What makes Retro Biosciences unique

• Retro Biosciences focuses on extending healthy human lifespan by targeting the cellular mechanisms of aging, a unique approach compared to traditional biotech firms.
• Their diversified business model, which includes cellular reprogramming, plasma-inspired therapeutics, and autophagy, provides a balanced pipeline of potential treatments.
• Significant initial funding of $180 million and partnerships like the $85 million deal with Multiply Labs for automated cell therapy manufacturing set Retro Biosciences apart in terms of financial backing and technological advancement.

Help us improve and share your feedback! Did you find this helpful?

YesNo